Skip to content

Gross margin at other companies

IAR
Integra LifeSciencesIART
51.9%-1.6pp
MiMedx Group logo
MiMedx GroupMDXG
81%-0.9pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
70.7%+3.6pp
Bioventus logo
BioventusBVS
68.7%+1.2pp
Artivion logo
ArtivionAORT
64.6%+0.6pp
Axogen logo
AxogenAXGN
75%+0.8pp

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×
P/S0.6×-0.3×

Profitability

See full
Operating margin0.5%
Net margin0.5%+0.3pp
FCF margin6.9%

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Calculated from Organogenesis Holdings Inc.’s reported figures.

Based on trailing twelve months.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 8, 2025, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s gross margin?
Organogenesis Holdings Inc. (ORGO) reported gross margin of 75.9% in Q1 2025.
How has Organogenesis Holdings Inc.'s gross margin changed year-over-year?
Organogenesis Holdings Inc.'s gross margin increased by 1.0% year-over-year, from 75.1% to 75.9%.
What is the long-term trend for Organogenesis Holdings Inc.'s gross margin?
Over 4 years (2020 to 2024), Organogenesis Holdings Inc.'s gross margin has grown at a 0.6% compound annual growth rate (CAGR), from 74.2% to 76%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.